RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE

GlaxoSmithKline Pharmaceuticals ROCE 2024

GlaxoSmithKline Pharmaceuticals ROCE

0.43

GlaxoSmithKline Pharmaceuticals Dividend yield

1.5 %

Ticker

GLAXO.NS

ISIN

INE159A01016

In 2024, GlaxoSmithKline Pharmaceuticals's return on capital employed (ROCE) was 0.43, a 63.8% increase from the 0.26 ROCE in the previous year.

GlaxoSmithKline Pharmaceuticals Aktienanalyse

What does GlaxoSmithKline Pharmaceuticals do?

GlaxoSmithKline (GSK) is a global pharmaceutical company focused on the development, manufacturing, and marketing of prescription medicines, vaccines, and consumer products. Founded in 2000 through the merger of Glaxo Wellcome and SmithKline Beecham, the company has become one of the leading players in the pharmaceutical and healthcare industry. GSK's history began in 1859 with the opening of a pharmacy in New Zealand by Joseph Edward Nathan. In 1904, physician and researcher Joseph Nathan Cohen founded Glaxo Laboratories, which specialized in the production of vitamin preparations. Over the years, the company expanded and eventually merged with Wellcome plc in 1995 to form Glaxo Wellcome. SmithKline Beecham was founded in 1830 and expanded through acquisitions and mergers in the following decades. In June 2000, Glaxo Wellcome and SmithKline Beecham merged to form GlaxoSmithKline. GSK's business model is based on research, development, and marketing of products aimed at improving patients' lives. The company has a wide range of products, including prescription medicines, vaccines, and consumer products. GSK operates in over 100 countries and employs over 100,000 people worldwide. GSK has various divisions, including pharmaceuticals, vaccines, and consumer healthcare. The pharmaceutical division is the company's core business and focuses on researching and developing innovative therapies in the areas of oncology, immunology, infectious diseases, and respiratory diseases. The company's vaccine division is involved in vaccine production and the development of new vaccine technologies. GSK is one of the largest vaccine manufacturers globally and produces vaccines against infectious diseases such as hepatitis A and B, meningococcal disease, pneumococcal disease, and HPV. The company's consumer healthcare division produces a wide range of products in the health and wellness sector, including dietary supplements, pain relievers, and skincare products under brands like Sensodyne, Voltaren, and Aquafresh. Some of GSK's most well-known products include the antidepressant Paxil, the asthma inhaler Advair, and the antimalarial medication Malarone. Additionally, GSK has played a leading role in addressing global health issues, such as developing a vaccine against Ebola and providing antiretroviral drugs for the treatment of HIV/AIDS. Overall, GlaxoSmithKline has established a strong position as one of the leading global pharmaceutical companies in recent years. The company pursues an innovative research and development strategy to promote forward-looking technologies that have the potential to change the way we perceive and treat diseases. With a strong focus on innovation, growth, and improving the quality of life for patients worldwide, GSK is on track to remain a significant player in the global healthcare industry. GlaxoSmithKline Pharmaceuticals ist eines der beliebtesten Unternehmen auf Eulerpool.com.

ROCE Details

Unraveling GlaxoSmithKline Pharmaceuticals's Return on Capital Employed (ROCE)

GlaxoSmithKline Pharmaceuticals's Return on Capital Employed (ROCE) is a financial metric that measures the company's profitability and efficiency with respect to the capital employed. It is calculated by dividing earnings before interest and tax (EBIT) by the employed capital. A higher ROCE indicates that the company is effectively utilizing its capital to generate profits.

Year-to-Year Comparison

Analyzing GlaxoSmithKline Pharmaceuticals's ROCE annually provides valuable insights into its efficiency in using its capital to generate profits. An increasing ROCE indicates improved profitability and operational efficiency, whereas a decrease might signal potential issues in capital utilization or business operations.

Impact on Investments

GlaxoSmithKline Pharmaceuticals's ROCE is a critical factor for investors and analysts for evaluating the company’s efficiency and profitability. A higher ROCE can make the company an attractive investment, as it often signifies that the firm is generating adequate profits from its employed capital.

Interpreting ROCE Fluctuations

Changes in GlaxoSmithKline Pharmaceuticals’s ROCE are attributed to variations in EBIT or the capital employed. These fluctuations offer insights into the company’s operational efficiency, financial performance, and strategic financial management, assisting investors in making informed investment decisions.

Frequently Asked Questions about GlaxoSmithKline Pharmaceuticals Stock

What is the ROCE (Return on Capital Employed) of GlaxoSmithKline Pharmaceuticals this year?

The ROCE of GlaxoSmithKline Pharmaceuticals is 0.43 undefined this year.

How has the ROCE (Return on Capital Employed) of GlaxoSmithKline Pharmaceuticals developed compared to the previous year?

The ROCE of GlaxoSmithKline Pharmaceuticals has increased by 63.8% increased compared to the previous year.

What does a high ROCE (Return on Capital Employed) mean for investors of GlaxoSmithKline Pharmaceuticals?

A high Return on Capital Employed (ROCE) indicates that GlaxoSmithKline Pharmaceuticals has efficient capital utilization and is able to achieve a higher return on its invested capital. This can be appealing to investors.

What does a low ROCE (Return on Capital Employed) mean for investors of GlaxoSmithKline Pharmaceuticals?

A low ROCE (Return on Capital Employed) can indicate that GlaxoSmithKline Pharmaceuticals has an inefficient utilization of its capital and may have difficulty in achieving a satisfactory return on its invested capital. This can be uncertain or unattractive for investors.

How does an increase in ROCE from GlaxoSmithKline Pharmaceuticals impact the company?

An increase in the ROCE of GlaxoSmithKline Pharmaceuticals can be an indicator of improved company efficiency and show that it is achieving higher profits in relation to its investments.

How does a reduction in the ROCE of GlaxoSmithKline Pharmaceuticals affect the company?

A decrease in ROCE of GlaxoSmithKline Pharmaceuticals can be an indicator of deteriorated efficiency of the company, indicating that it is generating lower profits in relation to its investments.

What are some factors that can influence the ROCE of GlaxoSmithKline Pharmaceuticals?

Some factors that can affect GlaxoSmithKline Pharmaceuticals's ROCE include efficiency in managing assets, profitability of investments, cost efficiency, and market conditions.

Why is the ROCE of GlaxoSmithKline Pharmaceuticals so important for investors?

The ROCE of GlaxoSmithKline Pharmaceuticals is important for investors as it is an indicator of the company's efficiency and shows how successful the company is in relation to its investments. A high ROCE can indicate strong financial performance of the company.

What strategic measures can GlaxoSmithKline Pharmaceuticals take to improve the ROCE?

To improve the ROCE, GlaxoSmithKline Pharmaceuticals can take measures such as increasing efficiency in asset management, optimizing investments, cost savings, and exploring new revenue sources. It is important for the company to conduct a thorough review of its operations to determine the best strategic actions to improve the ROCE.

How much dividend does GlaxoSmithKline Pharmaceuticals pay?

Over the past 12 months, GlaxoSmithKline Pharmaceuticals paid a dividend of 32 INR . This corresponds to a dividend yield of about 1.5 %. For the coming 12 months, GlaxoSmithKline Pharmaceuticals is expected to pay a dividend of 30.32 INR.

What is the dividend yield of GlaxoSmithKline Pharmaceuticals?

The current dividend yield of GlaxoSmithKline Pharmaceuticals is 1.5 %.

When does GlaxoSmithKline Pharmaceuticals pay dividends?

GlaxoSmithKline Pharmaceuticals pays a quarterly dividend. This is distributed in the months of August, August, August, July.

How secure is the dividend of GlaxoSmithKline Pharmaceuticals?

GlaxoSmithKline Pharmaceuticals paid dividends every year for the past 24 years.

What is the dividend of GlaxoSmithKline Pharmaceuticals?

For the upcoming 12 months, dividends amounting to 30.32 INR are expected. This corresponds to a dividend yield of 1.42 %.

In which sector is GlaxoSmithKline Pharmaceuticals located?

GlaxoSmithKline Pharmaceuticals is assigned to the 'Health' sector.

Wann musste ich die Aktien von GlaxoSmithKline Pharmaceuticals kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of GlaxoSmithKline Pharmaceuticals from 7/26/2023 amounting to 32 INR, you needed to have the stock in your portfolio before the ex-date on 6/30/2023.

When did GlaxoSmithKline Pharmaceuticals pay the last dividend?

The last dividend was paid out on 7/26/2023.

What was the dividend of GlaxoSmithKline Pharmaceuticals in the year 2023?

In the year 2023, GlaxoSmithKline Pharmaceuticals distributed 30 INR as dividends.

In which currency does GlaxoSmithKline Pharmaceuticals pay out the dividend?

The dividends of GlaxoSmithKline Pharmaceuticals are distributed in INR.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von GlaxoSmithKline Pharmaceuticals

Our stock analysis for GlaxoSmithKline Pharmaceuticals Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of GlaxoSmithKline Pharmaceuticals Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.